@article{oai:repo.qst.go.jp:00048358,
 author = {Shirai, Katsuyuki and Koto, Masashi and Demizu, Yuusuke and Suefuji, Hiroaki and Ohno, Tatsuya and Tsuji, Hiroshi and Okimoto, Tomoaki and Shioyama, Yoshiyuki and Saitou, Jyunnichi and Nemoto, Kenji and Nakano, Takashi and Kamada, Tadashi and 白井 克幸 and 小藤 昌志 and 出水 祐介 and 末藤 大明 and 大野 達也 and 辻 比呂志 and 沖本 智昭 and 塩山 善之 and 齋藤 淳一 and 根本 建二 and 中野 隆史 and 鎌田 正},
 issue = {7},
 journal = {Cancer Science},
 month = {Jul},
 note = {Abstract
\nThis study aimed to evaluate the clinical outcomes of patients with mucoepidermoid carcinomas in the head and neck treated with carbon-ion radiotherapy. Data from 26 patients who underwent carbon-ion radiotherapy in four facilities were analyzed in this multi-institutional retrospective study: the Japan Carbon-ion Radiation Oncology Study Group. The median follow-up time was 34 months. One patient experienced local recurrence, and the 3-year local control rate was 95%. One patient developed lymph node recurrence and five developed distant metastases. The 3-year progression-free survival rate was 73%. Five patients died, two of mucoepidermoid carcinoma and three of intercurrent disease. The 3-year overall survival rate was 89%. Acute mucositis and dermatitis of grade 3 or higher were experienced by 19% and 8% of patients, respectively; these improved with conservative therapy. Late mucositis and osteonecrosis of jaw were observed in 12% and 23% of patients, respectively. The 3-year cumulative rate of any late adverse event of grade 3 or higher was 14%. None of the patients died of the acute or late adverse events. Carbon-ion radiotherapy was efficacious and safe for treating mucoepidermoid carcinoma in this multi-institutional retrospective study (registration no. UMIN000024473). We are currently undertaking a prospective multicenter study.},
 pages = {1447--1451},
 title = {Multi-institutional retrospective study of mucoepidermoid carcinoma treated with carbon-ion radiotherapy.},
 volume = {108},
 year = {2017}
}